[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"digestive-system-neoplasm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:digestive-system-neoplasm":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,61,91,139],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":42,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":60},"100571099","target-specific-immunopet-imaging-of-digestive-system-carcinoma-100571099",false,"NCT06715839","Target-specific immunoPET Imaging of Digestive System Carcinoma","Development and Clinical Translation of immunoPET Imaging Probes for Digestive System Carcinoma","Inclusion Criteria:\n\n1. Aged 18-75 years old and of either sex；\n2. Histologically confirmed diagnosis of digestive system carcinoma or suspected digestive system carcinoma by diagnostic imaging;\n3. Capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the informed consent form (ICF) and this protocol.\n\nExclusion Criteria:\n\n1. Pregnancy；\n2. Severe hepatic and renal insufficiency;\n3. History of serious surgery in the last month;\n4. Allergic to antibody or single-domain antibody radiopharmaceuticals.","ALL","18 Years","75 Years",{"count":20,"type":21},400,"ESTIMATED","INTERVENTIONAL",[24],"NA","The aim of this study is to establish and optimize the target-specific PET\u002FCT imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging agents in digestive system malignant tumors will be evaluated.",[27,28,29,30,31,32,33,34,35,36,37,38,39,40,41],"Malignancy","Digestive Cancer","Digestive System Neoplasm","Digestive System Carcinoma","Digestive System Cancer","Liver Cancer","Stomach Cancer","Colon Cancer","Rectum Cancer","Pancreatic Cancer","Esophagus Cancer","Gallbladder Carcinoma","Small Intestine Cancer","Appendix Cancer","Bile Duct Carcinoma",[43,44,45,46,47],"human epidermal growth factor receptor 2 (HER2)","Trophoblast cell surface antigen 2 (TROP2)","Glypican-3 (GPC3)","Glycoprotein A33 (gpA33)","Nectin cell adhesion molecule-4 (Nectin-4)","RECRUITING","2025-12-25",{"date":51,"type":52},"2025-12-31","ACTUAL",{"date":54,"type":52},"2024-12-04",{"date":56,"type":21},"2027-09",{"name":58,"class":59},"RenJi Hospital","OTHER",1,{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":69,"targetDuration":4,"studyType":22,"phases":71,"briefSummary":72,"conditions":73,"keywords":74,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":60},"100360818","a-clinicobiological-database-in-metastatic-digestive-cancers-100360818","NCT03978078","A Clinicobiological Database in Metastatic Digestive Cancers","Development of a Prospective Clinicobiological Database in Metastatic Digestive Cancers","BCB-CBIO-DIG","Inclusion Criteria:\n\n1. Male or female ≥ 18 years old\n2. Histological documentation of adenocarcinoma of the colon or rectum, small intestine, pancreas, stomach, bile duct, oesophagus\n3. Patient who will receive a first or second line metastatic chemotherapy and\u002For targeted therapy\n4. Informed consent form (ICF) signed\n\nExclusion Criteria:\n\n1. Male or female \\\u003C 18 years old\n2. Non-adenocarcinoma histological type\n3. Patient already undergoing specific treatment (chemotherapy and\u002For targeted therapy) in 1st or 2nd metastatic line\n4. Pregnant and\u002For breastfeeding woman\n5. Patient not affiliated to a social security system\n6. Patient whose regular follow-up is impossible for psychological, family, social or geographical reasons\n7. Patient who is included in a Phase I-II therapeutic trial modifying usual management and involving additional and specific blood samples",{"count":70,"type":21},200,[24],"Creation of a collection of blood samples that will be collected before and then under treatment in patients with digestive adenocarcinoma during the 1st and 2nd metastatic line and which, depending on scientific progress, can be used for research projects aimed at developing tailored patient management strategies.",[29],[75,76,77,78,79,80,81],"colorectal","pancreas","stomach","oesophagus","bile duct","small intestine","cancer","2025-02-11",{"date":84,"type":52},"2025-02-12",{"date":86,"type":52},"2016-09-12",{"date":88,"type":21},"2031-09",{"name":90,"class":59},"Institut du Cancer de Montpellier - Val d'Aurelle",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":99,"enrollmentInfo":100,"targetDuration":102,"studyType":103,"phases":4,"briefSummary":104,"conditions":105,"keywords":113,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":138},"100400392","osprey-is-a-post-market-global-multicentre-observational-prospective-registry-100400392","NCT04493632","OSPREY is a Post-market, Global, Multicentre, Observational, Prospective Registry.","OncoSil Pancreatic Cancer Post-marketing Clinical REgistrY (OSPREY)","OSPREY","Inclusion Criteria:\n\n1. Patients with confirmed unresectable locally advanced pancreatic cancer (LAPC).\n2. Patients who undergo OncoSil™ implantation at an eligible treatment facility.\n3. Patients who have completed and signed the Patient Informed Consent Form (PICF) for the OSPREY Patient Registry.\n4. Pancreatic target tumour recommended size of \\\u003C7 cm (longest diameter) and \\\u003C110 cc volume.\n5. A clinically acceptable ECOG performance status.\n6. Patients ≥ 18 years of age at screening.\n7. To commence gemcitabine-based chemotherapy, (per Standard-of-Care are according to the approved prescribing schedule) post Registry enrolment.\n8. Adequate biochemical tests, coagulation profile, haematological, renal, and hepatic function as determined by the Treating Physician.\n\nExclusion Criteria:\n\n1. Patient Informed Consent Form (PICF) has not been completed and signed for the OSPREY Patient Registry.\n2. Patients treated with OncoSil™ within an approved interventional clinical study (company or investigator-sponsored).\n3. Evidence of distant metastases based on review of baseline CT scan.\n4. More than one primary lesion.\n5. In the opinion of the Treating Physician, EUS-directed implantation posing undue patient risk. This includes:\n\n   * where previous EUS-FNA was considered technically too difficult to perform;\n   * imaging demonstrates multiple collateral vessels surrounding or adjacent to the target tumour within the pancreas;\n   * presence (or significant risk) of varices near to the target tumour.\n6. Evidence of radiographic invasion into stomach or duodenum (if not certain, confirmation must be obtained prior to enrolment).\n7. In the setting of recent, clinically significant pancreatitis, implantation is not recommended.\n8. Pregnant or intending to commence a pregnancy within 12-months of the intended date of implantation or breastfeeding.\n9. Patients who have a known history of hypersensitivity to silicon or phosphorous, or any of the OncoSil™ components","90 Years",{"count":101,"type":21},500,"24 Months","OBSERVATIONAL","The OSPREY Patient Registry has been developed to collect and assess the performance and safety of the OncoSil™ device when used within the approved indication of unresectable, locally advanced pancreatic cancer, in combination with gemcitabine-based chemotherapy, within a real-world observational registry.\n\nThe Registry data will provide both complementary and contemporary information to the existing clinical data across various countries and will form part of the post-market clinical follow-up activities for OncoSil™. Therefore, the Registry will be implemented only in countries with regulatory (commercial) approval for the OncoSil™ device.",[106,29,107,108,109,110,111,112],"Pancreatic Neoplasm","Neoplasms by Site","Neoplasms","Endocrine Gland Neoplasm","Digestive System Disease","Pancreatic Diseases","Endocrine System Diseases",[36,114,115,116,117,118,119,120,121,122,123,124,125,126,127],"Pancreas","Metastases","Pancreatic tumor","Unresectable","Locally advanced","Implantable","Radiographic","Device","Phosphorous-32","OncoSil™","Brachytherapy","Gemcitabine","Nab-paclitaxel","Abraxane","2024-04-29",{"date":130,"type":52},"2024-04-30",{"date":132,"type":52},"2022-04-12",{"date":134,"type":21},"2027-10-01",{"name":136,"class":137},"OncoSil Medical Limited","INDUSTRY",9,{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":145,"targetDuration":4,"studyType":22,"phases":147,"briefSummary":148,"conditions":149,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":60},"100533239","nutritional-psychological-intervention-and-vomit-free-management-on-survival-and-quality-of-life-in-advanced-gastrointestinal-tumors-100533239","NCT06223230","Nutritional Psychological Intervention and Vomit-free Management on Survival and Quality of Life in Advanced Gastrointestinal Tumors","Inclusion Criteria:\n\n1. Age 18-75, male or female;\n2. Patients with advanced esophageal cancer, gastric cancer, liver cancer and colorectal cancer and other gastrointestinal tumors diagnosed by pathological histology or cytology;\n3. Expected survival ³ 8 weeks and able to receive long-term follow-up;\n4. Eastern Cooperative Oncology Group(ECOG)-Performance Status(PS) score of 0-2;\n5. First-line treatment receiving standard oncology treatment and nutritional psychological intervention and vomit-free management group (study group); first-line treatment receiving only standard oncology treatment group (control group);\n6. Voluntarily signing an informed consent form.\n\nExclusion Criteria:\n\n1. Other malignant tumors diagnosed within the previous 5 years, except for effectively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or effectively resected in situ cervical cancer or breast cancer;\n2. history of psychiatric illness prior to the diagnosis of the tumor\n3. patients who resist treatment\n4. patients with poorly controlled severe heart disease, liver or kidney insufficiency, severe anemia, multiple lymph node enlargement, leukopenia, etc;\n5. patients who are pregnant or have a pregnancy plan;\n6. patients who, in the judgment of the investigator, are not suitable for inclusion in this study.",{"count":146,"type":21},316,[24],"Aims to observe and evaluate the impact of survival and quality of life of patients with gastrointestinal tumors such as advanced esophageal, gastric, liver, pancreatic, and colorectal cancers through nutritional-psychological interventions versus no-vomit management compared to standard antitumor therapy alone",[31,29],"2024-01-28",{"date":152,"type":52},"2024-01-30",{"date":154,"type":52},"2022-06-01",{"date":156,"type":21},"2026-06-30",{"name":158,"class":59},"Renmin Hospital of Wuhan University"]